Matches 1 - 50 out of 276 1 2 3 4 5 6 >

AcclaimIP-ad

Match Document Document Title
9023796 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Antidotes for factor XA inhibitors and methods of using the same
 
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
8968725 Genipin cross-linked fibrin gels  
The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. Also provided...
8945897 Materials and methods for conjugating a water soluble fatty acid derivative to a protein  
The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water...
8889129 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
8865868 Conjugated proteins with prolonged in vivo efficacy  
The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a...
8828676 Methods for differentiating plasma-derived protein from recombinant protein in a sample  
The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation,...
8815250 Clotting factor-Fc chimeric proteins to treat hemophilia  
The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a...
8809016 Nucleic acids encoding modified vitamin K-dependent polypeptides  
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
8765915 Modified coagulation factor VIIa with extended half-life  
The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human...
8759292 Long-acting coagulation factors and methods of producing same  
Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and...
8754062 DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides  
The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed...
8741845 Lyophilized fibrin sealant for high volume hemorrhage  
ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or...
8741285 Method for treating a patient  
Intra-arterial administering at least one blood coagulation to a bleeding patient is provided, together with a pharmaceutical composition therefor.
8716448 Coagulation factor VII compositions and methods of making and using same  
The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and...
8710188 Factor IXa crystals, related complexes and methods  
The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
8697844 Method of purifying pegylated proteins  
The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood...
8686225 Monocot seed product comprising a human blood protein  
The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and...
8679783 Recombinant factor X with no glycosylation and method for preparing the same  
A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises...
8658597 Stabilised compositions of factor VII polypeptides  
The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these...
8647868 Compositions and methods for increasing production of recombinant gamma-carboxylated proteins  
Methods and cell lines for overexpressing functional gamma-carboxylated proteins are disclosed by way of genetically engineered cell lines which over-express VKORC1. Also disclosed is the...
8642738 Modified vitamin K-dependent polypeptides  
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
8637640 Blood coagulation protein conjugates  
The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized...
8632771 High molecular weight derivatives of vitamin K-dependent polypeptides  
Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both...
8633300 Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine  
The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction...
8598319 Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins  
The invention is related to a process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing freeze-dried concentrates of said...
8586711 Polymer-factor IX moiety conjugates  
Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among...
8536127 Protein stabilization in solution  
Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof...
8519103 Factor VII polypeptides that are modified and uses thereof  
Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are...
8513386 FVIII-independent FIX-mutant proteins for hemophilia a treatment  
The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins...
8476234 Long-acting coagulation factors and methods of producing same  
Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to...
8461115 Methods for local treatment with factor VII  
The present invention provides methods for the local treatment of bleeding in a subject and/or reducing unwanted effects associated with the systemic administration of thrombotic agents to a...
8455439 Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents  
The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or...
8454833 Counter-pressure filtration of proteins  
A method is disclosed for filtering a protein in a liquid mixture in a manner that does not substantially damage or otherwise limit the recovery of the protein in the filtration filtrate. The...
8431535 Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis  
The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of...
8415458 Modified vitamin K-dependent polypeptides  
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
8399632 Method for the purification of recombinant blood coagulation factor IX enriched in sulfated and/or phosphorylated molecules  
The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer...
8318904 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides  
The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for...
8293874 Recombinant factor X with no glycosylation and method for preparing the same  
A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises...
8277837 Hemostatic textile  
The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of...
8268783 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby...
8212003 Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof  
This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an...
8173777 Recombinant Factor X with no glycosylation and method for preparing the same  
A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises...
8168754 Modified vitamin K-dependent polypeptides  
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
8168753 Thrombin cleavable factor X analogues  
The invention relates to factor X analogues containing the thrombin-cleavable sequence Pro-Arg-Ala in place of the-sequence Thr-Arg-Ile of the activation site of native factor X. These factor X...
8071104 Neovascular-targeted immunoconjugates  
Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The...
8053410 Pegylated factor VII glycoforms  
The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked...
8026214 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides  
The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for...
8022187 FVIII-independent FIX-mutant proteins for hemophilia A treatment  
The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins...
8022031 Liquid composition of factor VII polypeptides  
A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a...
7968683 Factor IXa crystals, related complexes and methods  
The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
Matches 1 - 50 out of 276 1 2 3 4 5 6 >